In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity

• Published in: The FASEB journal Vol. 33; no. 4; p. 4921
• Main Authors: Le Barz, Mélanie, Daniel, Noëmie, Varin, Thibault V, Naimi, Sabrine, Demers-Mathieu, Véronique, Pilon, Geneviève, Audy, Julie, Laurin, Émilie, Roy, Denis, Urdaci, Maria C, St-Gelais, Daniel, Fliss, Ismaïl, Marette, André
• Format: Journal Article
• Language: English
• Published: United States 01.04.2019
• Subjects: Adipose Tissue - metabolism; Animals; Bifidobacterium animalis - physiology; Chemokines - metabolism; Cytokines - metabolism; Disease Models, Animal; Fatty Acids, Nonesterified - metabolism; Gastrointestinal Microbiome - physiology; Inflammation - metabolism; Lactobacillus rhamnosus - physiology; Male; Mice; Mice, Inbred C57BL; Obesity - diet therapy; Obesity - metabolism; Obesity - microbiology; Probiotics - therapeutic use; RNA, Ribosomal, 16S - genetics; gut integrity; dairy products; insulin resistance
• ISSN: 1530-6860
• DOI: 10.1096/fj.201801672R

Given the growing evidence that gut dysfunction, including changes in gut microbiota composition, plays a critical role in the development of inflammation and metabolic diseases, the identification of novel probiotic bacteria with immunometabolic properties has recently attracted more attention. Herein, bacterial strains were first isolated from dairy products and human feces and then screened in vitro for their immunomodulatory activity. Five selected strains were further analyzed in vivo, using a mouse model of diet-induced obesity. C57BL/6 mice were fed a high-fat high-sucrose diet, in combination with 1 of 3 Lactobacillus strains (Lb38, L. plantarum; L79, L. paracasei/casei; Lb102, L. rhamnosus) or Bifidobacterium strains (Bf26, Bf141, 2 different strains of B. animalis ssp. lactis species) administered for 8 wk at 10 colony-forming units/d. Whereas 3 strains showed only modest (Lb38, Bf26) or no (L79) effects, Lb102 and Bf141 reduced diet-induced obesity, visceral fat accretion, and inflammation, concomitant with improvement of glucose tolerance and insulin sensitivity. Further analysis revealed that Lb102 and Bf141 enhanced intestinal integrity markers in association with selective changes in gut microbiota composition. We have thus identified 2 new potential probiotic bacterial strains with immunometabolic properties to alleviate obesity development and associated metabolic disturbances.-Le Barz, M., Daniel, N., Varin, T. V., Naimi, S., Demers-Mathieu, V., Pilon, G., Audy, J., Laurin, E., Roy, D., Urdaci, M. C., St-Gelais, D., Fliss, I, Marette, A. In vivo screening of multiple bacterial strains identifies Lactobacillus rhamnosus Lb102 and Bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity.